Gender, male [n (%)] |
30 (44.1%) |
17 (27.0%) |
0.047 |
Male/female ratio |
0.78 |
0.36 |
|
Age, years [mean (range)] |
53.1 (20–85) |
47.4 (20–76) |
0.035 |
AE episode, duration [n (%)] |
|
|
0.181 |
1–3 hours |
2 (2.9%) |
3 (4.8%) |
|
3–6 hours |
9 (13.2%) |
6 (9.5%) |
|
6–12 hours |
14 (20.6%) |
15 (23.8%) |
|
12–24 hours |
9 (13.2%) |
13 (20.6%) |
|
24–28 hours |
12 (17.7%) |
17 (27.0%) |
|
2–3 days |
15 (22.1%) |
8 (12.7%) |
|
3–6 days |
7 (10.3%) |
1 (1.6%) |
|
AE episodes past 12 months [median (iqr)] |
6 (3–14) |
4.5 (2–12) |
0.390 |
Treatment [n (%)] |
47 (69.12%) |
52 (82.54%) |
0.096 |
H1-antihistamine [n (%)] |
36 (52.94%) |
50 (79.37%) |
0.001 |
single dose [n (%)] |
24 (35.29%) |
27 (42.86%) |
0.375 |
updose [n (%)] |
12 (17.65%) |
23 (36.51%) |
0.015 |
double dose [n (%)] |
10 (14.71%) |
13 (20.63%) |
0.373 |
triple dose [n (%)] |
1 (1.47%) |
4 (6.35%) |
0.145 |
quadruple dose [n (%)] |
1 (1.47%) |
6 (9.52%) |
0.041 |
Corticosteroid [n (%)] |
9 (13.24%) |
13 (20.63%) |
0.694 |
Omalizumab [n (%)] |
3 (4.41%) |
0 |
0.086 |
Others [n (%)] |
4 (5.88%) |
9 (14.29%) |
0.285 |
Number of treatments [median (iqr)] |
1 (1–1) |
1 (1–2) |
0.040 |
Patient visits to an emergency department since diagnosis [n (%)] |
41 (60.3%) |
45 (71.4%) |
0.180 |
Number of visits to an emergency department [n
(%)]†
|
|
|
0.333 |
0 visits |
0 |
2 (4.2%) |
|
1 visits |
9 (22.5%) |
7 (14.6%) |
|
2 visits |
10 (25%) |
7 (14.6%) |
|
3 visits |
2 (5%) |
7 (14.6%) |
|
4 visits |
7 (17.5%) |
5 (10.4%) |
|
5 visits |
4 (10%) |
6 (12.5%) |
|
>5 visits |
8 (20%) |
14 (29.2%) |
|
Number of visits to an emergency department past 12 months [median
(iqr)] |
1 (0–2) |
2 (1–4) |
0.015 |